BVAC B

Drug Profile

BVAC B

Alternative Names: Autologous B cell and monocyte presenting HER2/neu antigen - Cellid; BVAC-B

Latest Information Update: 15 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellid Company
  • Class Vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Helper-inducer T-lymphocyte stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 08 Feb 2018 Cellid plans a phase I trial for Gastric cancer (Recurrent, Second-line therapy or greater) in South Korea (NCT03425773)
  • 24 Jan 2018 Preclinical trials in Solid tumours in South Korea (IV)
  • 24 Jan 2018 Korea Food and Drug Administration (KFDA) approves clinical trial application for BVAC B in Gastric cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top